Weekly Report: what happened at OGEN last week (0219-0223)?
Weekly Report · 21h ago
Weekly Report: what happened at OGEN last week (0212-0216)?
Weekly Report · 02/19 09:41
Oragenics Inc Announces Executive Leadership Transition
TipRanks · 02/12 22:04
Oragenics says CEO Murphy steps down from the role
Oragenics says CEO Murphy steps down from the role Feb. 12. Murphy will remain a member of the company’s board of directors. The firm has named its president, Michael Redmond, as the interim principal executive officer. Oragenics, Inc. (OGEN)
Seeking Alpha · 02/12 21:47
Oragenics , Chief Executive Officer Kimberly Murphy Enter Mutually Agreeable Separation Agreement
Murphy will continue to serve as a member of the company's board of directors. Charlie Pope, the Company's Chairman of the Board, will become Executive Chairman. The Company's President will become interim Principal Executive Officer, effective February 12, 2024, the company says.
Benzinga · 02/12 21:43
Weekly Report: what happened at OGEN last week (0205-0209)?
Weekly Report · 02/12 09:38
OGEN, SSP and ZENV among mid-day movers
Seeking Alpha · 02/07 17:58
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Societal CDMO (NASDAQ:SCTL) shares moved upwards by 23.4% to $0.57 during Wednesday's pre-market session. Elicio Therapeutics and PepGen also moved upwards. Apollomics shares rose by 19.86% during the session. Losers CytoMed Therapeutic and GRI Bio stock declined by 16.9%.
Benzinga · 02/07 13:06
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Exicure (NASDAQ:XCUR) stock rose 70.0% to $0.94 during Monday's after-market session. Sharps Technology (NASdaq:STSS) shares increased by 17.57%. Oragenics (AMEX:OGEN) shares rose by 7.79%. ThermoGenesis Holdings ( NASDAQ:THMO) stock decreased by 8.0%.
Benzinga · 02/05 21:31
Oragenics Preparing For Phase II Trial In Treatment Of Concussion - Quick Facts
NASDAQ · 02/05 14:00
Oragenics Prepares Phase II Clinical Trials To Treat Concussion
Benzinga · 02/05 13:20
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
10 Bioscience stock is rocketing more than 59% alongside heavy pre-market trading this morning. Chenghe Acquisition shares are soaring over 37% following shareholder approval for a merger plan. Clinical trial data, company merger plans, bankruptcy filings and more are the biggest pre- market stock movers.
Investorplace · 02/05 12:25
Weekly Report: what happened at OGEN last week (0129-0202)?
Weekly Report · 02/05 09:40
12 Health Care Stocks Moving In Thursday's After-Market Session
MyMD Pharmaceuticals shares increased by 9.3% to $0.15 during Thursday's after-market session. PaxMedica shares rose 8.58% and Codexis shares rose 5.81%. Kiora Pharmaceuticals (NASDAQ:KPRX) stock declined by 10.6% during the session.
Benzinga · 02/01 21:31
Why C.H. Robinson Shares Are Trading Lower By Over 12%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
C.H. Robinson Worldwide shares dipped 12.6% to $73.49 on Thursday. The company reported worse-than-expected fourth-quarter financial results. Minim, Inc. Shares climbed 57.3% in today's mid-day session. Etsy Inc. And Oragenics Inc. Were also among the stocks moving in Thursday's session.
Benzinga · 02/01 18:17
Why Nextracker Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket
Shares of Nextracker Inc. Rose sharply during today's pre-market trading after the company reported better-than-expected third-quarter financial results. The company reported quarterly earnings of 96 cents per share. Elevai Labs, Inc. And Trinity Biotech reported strong results on Wednesday.
Benzinga · 02/01 12:51
12 Health Care Stocks Moving In Wednesday's Intraday Session
Sonoma Pharmaceuticals (NASDAQ:SNOA) shares moved upwards by 36.0% to $0.21 during Wednesday's regular session. 2seventy bio shares rose 34.28% in the session. Vaxart (VXRT) shares rose 26.73% and Jin Medical International (Jin) shares increased by 20.48%. Evaxion Biotech (EVAX) shares declined by 33.1% during the day.
Benzinga · 01/31 17:31
Webull provides a variety of real-time OGEN stock news. You can receive the latest news about Oragenics through multiple platforms. This information may help you make smarter investment decisions.
About OGEN
Oragenics, Inc. is a development-stage company that is focused on fighting infectious diseases, including those caused by coronaviruses and multidrug-resistant organisms. Its lead product NT-CoV2-1 is an intranasal vaccine candidate to prevent coronavirus disease (COVID-19) from the SARS-CoV-2 virus and variants thereof. Its lantibiotics program features a novel class of antibiotics against bacteria its research has shown may be applicable to multiple antibiotic-resistant organisms. Its Antibiotics product is a semi-synthetic analog of MU1140, which is a member of lantibiotic class of antibiotics. Its product pipeline also includes ONP-002, which is a fully synthetic neurosteroid being developed to treat mild traumatic brain injury (mTBI), also known as concussion, and for treating Niemann Pick Disease Type C (NPC). Through its wholly owned subsidiary, Noachis Terra, is engaged in the research and development stage for its new Terra CoV-2 and NT-CoV2-1 vaccine product candidates.